Tarsons Products growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+7.7%+32.4%—
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+6.5%+10.9%—
−55.6%−18.8%—
−51.9%−30.2%—
−52.0%−30.1%—
+9.8%+11.1%+34.0%
+0.7%+2.8%+7.7%
+3.7%+11.2%+35.9%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

TARSONS₹303.95

Tarsons Products Limited

· Pharma & Health
₹ CrorePeersFISCHERLAXMIDENTLFABTECHGKBMcap ₹1,617 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth——+32.4+7.7—
EBITDA Growth——+10.9+6.5—
EBIT Growth——-18.8-55.6—
Net Income Growth——-30.2-51.9—
EPS Growth——-30.1-52.0—
Total Assets Growth—+34.0+11.1+9.8—
Total Equity Growth—+7.7+2.8+0.7—
Cash from Operations Growth—+35.9+11.2+3.7—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.